IP Library Patent Application 16005633
Patent Application
App. No. 16/005,633

DEVICE AND METHOD OF COLLECTION FOR RNA VIRUSES

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/005,633
Abstract

The present disclosure generally relates to a method and device for inactivation and dry storage, under ambient conditions, of a biological sample containing RNA virus. Methods for collecting and recovering RNA from a biological sample and subsequent analysis for a virus are also provided.

Claims (10)

1 .- 24 . (canceled)

25 . A collection device for inactivation and dry storage of a biological sample containing an RNA virus without degradation of viral RNA, the device comprising:

providing a non-dissolvable, dry, solid matrix incorporated with a composition, the composition comprising at least one protein denaturant, at least one acid or acid-titrated buffer reagent impregnated therein in a dry state;

a frame for holding the dry solid matrix; and

a storage sleeve capable of encasing the frame and dry solid matrix after collection of the sample.

26 . The device of claim 25 , wherein the acid comprises acetic acid, citric acid, tartaric acid, phosphoric acid, hydrochloric acid, Tris(2-carboxyethyl) phosphine-hydrochloric acid (TCEP-HCl), oxidized Tris(2-carboxyethyl) phosphine-hydrochloric acid (TCEP-O—HCl), sulfuric acid, nitric acid, vanillic acid, 3-(N-morpholino)propanesulfonic acid or combinations thereof.

27 . The device of claim 25 , where the composition further comprises a UV protectant, a free-radical scavenger, a chelator, a reducing agent or combinations thereof.

28 . The device of claim 27 , where the composition further comprises an RNase inhibitor.

29 . The device of claim 28 wherein the RNase inhibitor comprises at least one of a triphosphate salt, pyrophosphate salt, vanadyl ribonucleoside complex (VCR), or sodium pyrophosphate.

30 . The device of claim 27 , wherein the reducing agent is selected from the group consisting of dithiothreitol (DTT), 2-mercaptoethanol (2-ME), tris(2-carboxyethyl)phosphine (TCEP), tris(2-carboxyethyl)phosphine hydrochloride (TCEP-HCl) and a combination thereof.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 7, 2020
From: GE HEALTHCARE UK LIMITED
To: GLOBAL LIFE SCIENCES SOLUTIONS OPERATIONS UK LTD
Reel/Frame 054300/0369 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 5, 2020
From: GENERAL ELECTRIC COMPANY
To: GE HEALTHCARE UK LIMITED
Reel/Frame 053981/0329 →
CORRECTIVE ASSIGNMENT TO CORRECT THE THIRD ASSIGNOR'S NAME PREVIOUSLY RECORDED AT REEL: 046053 FRAME: 0654. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jun 13, 2018
From: KVAM, ERIK LEEMING; DUTHIE, ROBERT SCOTT; NELSON, JOHN RICHARD
To: GENERAL ELECTRIC COMPANY
Reel/Frame 046339/0165 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 12, 2018
From: KVAM, ERIK LEEMING; DUTHIE, ROBERT SCOTT; NELSON, JARED RICHARD
To: GENERAL ELECTRIC COMPANY
Reel/Frame 046053/0654 →